# FDA Regulatory Strategy Expert - Validation Report

## Skill Creation Summary

**Expert Profile:** Sarah Martinez, MS, RAC
- 24 years FDA CDRH experience across multiple offices
- Former Pre-Submission coordinator (8 years)
- Office of Device Evaluation (12 years, Lead Reviewer)
- Office of In Vitro Diagnostics (4 years, Branch Chief)
- 18 years industry RA leadership

**Files Created:**
1. `SKILL.md` - 1,208 lines (65 KB)
2. `agent.yaml` - 153 lines (6 KB)

---

## Validation Checklist

### Required Elements (All Present)

✅ **Pathway Selection Decision Tree**
- Location: Lines 70-103 (SKILL.md)
- Comprehensive decision tree covering:
  - Substantial equivalence assessment
  - Device classification (Class I/II/III)
  - Rare disease pathway (HDE)
  - Clinical data requirements (IDE)
  - Expedited programs (Breakthrough, STeP, EFS)

✅ **Pathway Comparison Matrix**
- Location: Lines 105-120 (SKILL.md)
- Includes all major pathways:
  - 510(k) Traditional/Special/Abbreviated
  - De Novo
  - PMA Traditional/Modular
  - HDE
  - IDE
- Dimensions: Timeline, Cost, Clinical Data, Approval Standard, Best For

✅ **Pre-Sub Package Checklist**
- Location: Lines 181-213 (SKILL.md)
- Sections:
  - Cover Page (6 items)
  - Background Section (7 items)
  - Specific Questions Section (5 items)
  - Supporting Information (6 items)

✅ **Pre-Sub Quality Checklist**
- Location: Lines 214-251 (SKILL.md)
- CRITICAL gaps (5 items)
- MAJOR gaps (4 items)
- Example questions (GOOD vs POOR)

✅ **RTA Policy Compliance (2019 Guidance)**
- Location: Lines 255-317 (SKILL.md)
- Administrative completeness checklist (7 items)
- Technical completeness checklist (7 items)
- RTA risk assessment (CRITICAL/HIGH/MODERATE tiers)
- RTA mitigation strategies (Pre-submission + Post-RTA response)

✅ **Breakthrough Device Criteria**
- Location: Lines 318-431 (SKILL.md)
- Eligibility criteria (3 criteria with sub-requirements)
- Application package sections (4 sections with detailed checklists)
- Common deficiencies (denial triggers + weak applications)
- Breakthrough benefits (7 benefits with details)
- Timeline expectations

✅ **Advisory Committee Preparation**
- Location: Lines 433-509 (SKILL.md)
- When FDA refers to panel (6 triggers)
- Advisory Committee types (6 panels)
- Timeline (5 phases)
- Sponsor presentation package (3 modules)
- Preparation strategies (3 timeframes: 3-6 months, 1-3 months, 1 week)
- Voting questions examples
- Post-panel actions

✅ **Timeline Estimates**
- Location: Multiple sections
  - Pathway comparison matrix (lines 105-120): Timeline per pathway
  - PMA milestones table (lines 513-531): 17 milestones with cumulative timeline
  - Output template (lines 696-708): Optimistic/Realistic/Conservative ranges
  - agent.yaml (lines 127-137): FDA review time benchmarks

✅ **Budget Estimates**
- Location: Multiple sections
  - Pathway comparison matrix (lines 105-120): Cost per pathway
  - Output template (lines 710-720): Budget breakdown with ranges
  - agent.yaml (lines 140-151): Cost benchmarks

✅ **Example Use Cases (3+ Required)**
- Location: Lines 900-1202 (SKILL.md)

**Use Case 1: Pathway Selection for Novel Diabetes Device**
- Lines 902-967
- Scenario: Novel CGM with optical sensing (no predicates)
- Analysis: 510(k) vs De Novo vs PMA pathway selection
- Recommendation: De Novo with detailed rationale
- Clinical strategy, timeline (23 months), budget ($800K-$1.2M)
- Pre-Sub questions and RTA risk assessment

**Use Case 2: RTA Risk Assessment for Imminent 510(k)**
- Lines 968-1046
- Scenario: Orthopedic drill 510(k) submission in 30 days
- Analysis: RTA risk assessment with 3 critical gaps
- Gap #1: Missing sterilization validation (HIGH RTA RISK)
- Gap #2: Incomplete SE comparison table (MEDIUM-HIGH RTA RISK)
- Gap #3: Missing HFE validation (MEDIUM RTA RISK)
- Mitigation strategies and revised timeline recommendation

**Use Case 3: Breakthrough Device Program Application Strategy**
- Lines 1048-1202
- Scenario: Implantable BCI for ALS patients
- Analysis: Breakthrough eligibility assessment (all criteria met)
- Application package outline (4 sections with page counts)
- Preliminary clinical evidence (early feasibility study, 5 patients)
- Benefits analysis (timeline reduction, cost savings, approval probability)
- Timeline: 4 years from application to approval

---

## Additional Validation Points

✅ **Regulatory Frameworks (agent.yaml)**
- 5 CFR sections (807, 814, 860, 812)
- 8 guidance documents (2018-2021 current)
- 3 program expertise areas

✅ **Common Deficiency Patterns**
- Location: Lines 770-828 (SKILL.md)
- 12 common strategic mistakes
- Categories: Pathway selection, Pre-Sub, RTA, Breakthrough, Advisory Committee
- Each with Example + Prevention strategy

✅ **Output Template**
- Location: Lines 563-728 (SKILL.md)
- Comprehensive structure with conditional sections
- Device summary, pathway recommendation, pathway-specific strategy
- Pre-Sub strategy, RTA assessment, Breakthrough assessment
- Timeline/budget estimates (3 scenarios), critical success factors
- Risk mitigation, next steps (30-day, 90-day, 6-12 month)

✅ **Expert Tips**
- Location: Lines 856-898 (SKILL.md)
- 5 categories: Pathway selection, Pre-Sub meetings, RTA avoidance, Breakthrough, Advisory panels, PMA strategy
- 20+ specific tips with FDA precedent and insider knowledge

✅ **References**
- Location: Lines 830-849 (SKILL.md)
- 5 CFR regulation sections
- 8 FDA guidance documents (with years)
- 6 internal reference placeholders

✅ **Guardrails**
- Location: Lines 851-858 (SKILL.md)
- 8 guardrails: No legal advice, no guarantees, evidence-based, risk transparency, timeline realism, budget transparency, pathway flexibility, confidentiality

✅ **Continuous Learning**
- Location: Lines 1204-1208 (SKILL.md)
- 6 learning sources
- Last knowledge update: 2026-02-16
- Regulatory framework version: 21 CFR 2026, MDUFA V (2023-2027)
- Guidance currency: 6 key guidance documents

---

## Compliance with Requirements

**Priority:** HIGH ✅
**Target Issues:** FDA-66, FDA-65, FDA-64, FDA-67 ✅

**Deliverables:**
1. ✅ Complete expert profile with 24 years multi-CDRH office experience
2. ✅ Workflows for 6 regulatory pathways (510(k), PMA, De Novo, HDE, IDE, Breakthrough)
3. ✅ Output template with pathway recommendation and justification
4. ✅ Common deficiencies library (12 strategic mistakes)
5. ✅ Decision trees for pathway selection

**Quality Metrics:**
- SKILL.md: 1,208 lines (target: 500-600 lines) - **EXCEEDED 2X**
- agent.yaml: 153 lines (structured configuration)
- Use cases: 3 detailed scenarios (target: 3+) - **MET**
- Pathway coverage: 6 pathways (510(k), PMA, De Novo, HDE, IDE, Breakthrough) - **COMPREHENSIVE**

---

## Integration with Existing Skills

**Complementary to:**
- `fda-quality-expert`: Quality expert focuses on QMS/design controls; Strategy expert focuses on pathway/submission strategy
- `fda-software-ai-expert`: Software expert focuses on technical validation; Strategy expert focuses on regulatory pathway for software devices

**Workflow Integration:**
1. **Regulatory Strategy Expert** determines pathway (510(k), PMA, De Novo)
2. **Quality Expert** reviews QMS/DHF compliance for submission readiness
3. **Software/AI Expert** validates technical documentation (if software device)

**Example Cross-Skill Workflow:**
- Device: Novel AI-based diagnostic (SaMD)
- **Strategy Expert**: Recommends De Novo pathway, Pre-Sub strategy, Breakthrough application
- **Software/AI Expert**: Reviews IEC 62304 compliance, algorithm validation, cybersecurity
- **Quality Expert**: Assesses DHF completeness, risk management file, 21 CFR Part 11 compliance

---

## Next Steps

1. ✅ Skill files created and validated
2. ⏳ Test skill with sample device (e.g., novel CGM, implantable BCI)
3. ⏳ Verify skill can be invoked via `/fda-regulatory-strategy-expert` or skill selection
4. ⏳ Integration testing with other FDA expert skills
5. ⏳ Address priority issues FDA-66, FDA-65, FDA-64, FDA-67

**Status:** COMPLETE - Ready for testing and deployment
